Philips showcases clinical data and solutions designed to deliver better cardiac care with greater efficiency at TCT 2022

Rhea-AI Summary

Royal Philips (NYSE: PHG) presented its latest innovations in cardiology at the Transcatheter Cardiovascular Therapeutics (TCT) annual meeting held in Boston from September 16-19, 2022. Key highlights include global consensus data advocating the use of intravascular ultrasound (IVUS) for peripheral vascular disease procedures. Philips emphasized the importance of its technology in improving patient outcomes and efficiencies in clinical settings. Notable products showcased include the VeriSight Pro catheter and the EchoNavigator 4.0 imaging system, enhancing diagnostic and therapeutic capabilities in cardiac care.

Positive

• Global consensus data recommends IVUS for peripheral vascular procedures, indicating a robust market demand.
• Showcasing advanced technologies like VeriSight Pro and EchoNavigator 4.0 could strengthen Philips' competitive position in the cardiology field.
• Clinical data presented might enhance provider confidence in Philips' products, potentially boosting market adoption.

Negative

• None.

September 16, 2022

• Global consensus data recommends the use of intravascular ultrasound (IVUS) in many peripheral vascular disease (PVD) procedures
• Philips Engagement Hub at TCT to feature a range of physician-led discussions, in-depth symposia, and hands-on trainings that address some of today’s most pressing cardiology challenges

Amsterdam, the Netherlands – Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, will showcase its latest innovations and cardiology solutions designed to strengthen clinical confidence, build efficiency throughout the care pathway and improve cardiac care experiences at the Transcatheter Cardiovascular Therapeutics (TCT) annual meeting (Boston, USA, September 16-19). In addition, the company will present key clinical data, including global consensus data which highlights the importance of IVUS for both arterial and venous procedures.

“At Philips, we are fully focused on supporting physicians to improve the health and well-being of the patients they serve. Some of the most ground-breaking work we are doing to achieve this is happening in cardiology,” said Chris Landon, General Manager, Image Guided Therapy Devices at Philips. “TCT attendees will have the opportunity to see first-hand our complete set of solutions designed to provide clinicians with the diagnostic and therapeutic devices they need to optimize the workflow and improve outcomes for each individual patient.”

An interactive cardiology experience with Philips at TCT 2022
Visitors to TCT 2022 will have access to Philips’ latest solutions, plus opportunities to engage with clinical experts and experience innovative cardiac solutions. Philips will be hosting hands on demonstrations, symposia and discussions on topics that range from how to start an ultra-low contrast PCI program, to amplifying gender equality in medicine. Visitors will also have the opportunity to learn more about Philips Azurion, the next generation image-guided therapy platform, Philips Interventional Applications Platform – IntraSight, which optimizes lab performance with its imaging, physiology and co-registration tools, and the Philips iFR (Instant Wave-free Ratio) with its evidence-based methodology that improves outcomes, saves time, and reduces patient discomfort. Philips iFR is the only resting index to earn a Class IA guideline recommendation from the ACC/AHA/SCAI and ESC based on clinical evidence of its accuracy [1, 2].

Philips’ latest technology advancements in diagnostic, interventional and monitoring solutions at TCT 2022 include:

• Philips 3D Intracardiac Echocardiography Catheter – VeriSight Pro: Used with Philips’ premium cardiology ultrasound systems EPIQ CVx and CVxi, the VeriSight Pro offers superior 2D and 3D live-image guidance for a wide range of procedures in structural heart disease and electrophysiology.
  
  
• Simplifying coronary and peripheral atherectomy and lead extraction procedures with Philips Laser System – Nexcimer: The only system compatible with catheters that have Level I clinical data for ISR atherectomy and that can also support lead extraction procedures (the removal of pacemaker or defibrillator leads around the heart) [3,4].
  
  
• Philips live fluoroscopy-echo fusion imaging  – EchoNavigator 4.0: Used with the Philips Image Guided Therapy System - Azurion - and Philips’ premium cardiology ultrasound system – EPIQ CVxi, the new EchoNavigator Release 4.0 empowers heart teams with greater control of live fusion imaging plus new anatomical modeling and transeptal guidance during minimally-invasive structural heart disease procedures.

Published clinical data presented at TCT 2022
IVUS consensus and large-scale, real-world data summary: On Saturday, September 17, at 11:30am ET in the Philips Engagement Hub,  Eric A. Secemsky, MD, Interventional Cardiologist at Beth Israel Deaconess Medical Center and Assistant Professor of Medicine at Harvard Medical School in Boston, MA, will review two critically important data sets released in late 2021 that highlight the importance of IVUS for both arterial and venous procedures, including the new consensus document from 30 global vascular experts, which recommends routine use of IVUS as a preferred imaging modality in all phases in many peripheral vascular disease (PVD) procedures, published in the August 2022 issue of the Journal of the American College of Cardiology: Cardiovascular Interventions as “Appropriate Use of Intravascular Ultrasound During Arterial and Venous Lower Extremity Interventions.”

New study validates ambulatory monitoring as a valuable, cost-neutral tool
Many patients with severe symptomatic aortic stenosis (SAS) are treated with a transcatheter aortic valve replacement (TAVR) – a minimally invasive procedure that replaces a diseased aortic valve with a prosthetic valve. As an alternative to open-heart aortic valve replacement surgery, TAVR treatment offers several benefits for symptomatic SAS patients, including reduced length of hospital stay and an increased likelihood of home discharge [5].

A recent study, “Costs and Outcomes of Mobile Cardiac Outpatient Telemetry Monitoring Post-Transcatheter Aortic Valve Replacement,” published in the August issue of the Journal of Comparative Effectiveness Research, examined the impact that using Philips MCOT (Mobile Cardiac Outpatient Telemetry) had on patient outcomes and value of high-quality care following TAVR procedures. The study revealed that MCOT-monitored TAVR hospital patients were more than 16% more likely to receive a permanent pacemaker through a scheduled physician referral than unmonitored patients (100% MCOT vs 83.5% non-MCOT), helping to avoid unplanned readmissions [6]. The study illustrates that prescribing MCOT to patients post-TAVR may provide an opportunity for improved health outcomes or cost savings by monitoring for arrhythmic disturbances, and, if detected, allowing for timely intervention via pacemaker and the avoidance of costly and dangerous emergency care.

For the full calendar of events, as well as general information about Philips’ presence at the show, visit www.philips.com/TCT. Visit the Philips Engagement Hub to experience innovative cardiac solutions and follow the #TCT2022 conversation on @PhilipsLiveFrom throughout the event.

Refer to full Philips Laser System device labeling and instructions for important safety information. Caution: Federal law restricts this device to sale by or on the order of a physician.

[1] Lawton J. et al. 2021 ACC/AHA/SCAI Guideline for Coronary Artery Revascularization. JACC. 2022;79(2):e21-e129.
[2] 2018 ESC/EACTS Guidelines on myocardial revascularization: The task force on myocardial revascularization of the European society of cardiology (ESC) and European association for cardio-thoracic surgery (EACTS). Eur Heart J. 2018;00:1-96.
[3]  Philips Laser System Data Sheet Specifications.
[4] Dippel et al. Randomized Controlled Study of Excimer Laser Atherectomy for Treatment of Femoropopliteal In-stent Restenosis: Initial ISR Results (2015). JACC 8(1): 92-101.
[5] Arora S, Strassle PD, Kolte D, et al. Length of stay and discharge disposition after transcatheter 283 versus surgical aortic valve replacement in the United States. Circ Cardiovasc Interv. 2018;11(9). 284 doi:10.1161/circinterventions.118.006929.
[6] Belinda A Mohr, PhD1, et al. Impact of Mobile Cardiac Outpatient Telemetry Post-Transcatheter Aortic Valve Replacement on Costs and Outcomes: A Medicare Claims Analysis. J. Comp. Eff. Res. 2022.  https://www.futuremedicine.com/doi/10.2217/cer-2022-0112.

For further information, please contact:

Joost Maltha
Philips Global Press Office
Tel.: +31 610 558116
E-mail: joost.maltha@philips.com

Fabienne van der Feer
Philips Image Guided Therapy
Tel: + 31 622 698 001
E-mail: fabienne.van.der.feer@philips.com

About Royal Philips

Royal Philips (NYSE: PHG, AEX: PHIA) is a leading health technology company focused on improving people's health and well-being and enabling better outcomes across the health continuum – from healthy living and prevention, to diagnosis, treatment, and home care. Philips leverages advanced technology and deep clinical and consumer insights to deliver integrated solutions. Headquartered in the Netherlands, the company is a leader in diagnostic imaging, image-guided therapy, patient monitoring and health informatics, as well as in consumer health and home care. Philips generated 2021 sales of EUR 17.2 billion and employs approximately 79,000 employees with sales and services in more than 100 countries. News about Philips can be found at www.philips.com/newscenter.

Attachments

• Philips EchoNavigator 4.0
• Philips Intravascular Ultrasound
• Philips 3D Intracardiac Echocardiography Catheter – VeriSight Pro

FAQ

What new technologies did Philips showcase at TCT 2022?

Philips showcased innovations such as the VeriSight Pro catheter for 3D imaging and the EchoNavigator 4.0 for live fusion imaging in cardiac procedures.

What is the significance of IVUS in peripheral vascular disease procedures?

IVUS is recommended by global consensus data as a preferred imaging modality, highlighting its critical role in improving clinical outcomes.

When is TCT 2022 taking place?

The Transcatheter Cardiovascular Therapeutics (TCT) annual meeting is held from September 16-19, 2022, in Boston, USA.

What are the expected outcomes of Philips' new cardiac solutions?

Philips' innovations aim to enhance diagnostic accuracy and improve patient outcomes during cardiology procedures.